Aggregated life energy
Care for human health
Win trust by reputation and create efficiency
Insufficient innovation ability of domestically produced drugs, related to lack of participation of clinicians
Accelerating the progress of new drug research and development in China requires institutional and policy support, and more needs the source of innovation, and the old can not follow suit.
A few days ago, the National Health and Family Planning Commission announced the results of the first batch of drug price negotiations. The prices of the three best-selling life-saving drugs were swayed by more than 50%, which is called “the hard-won progress of the national drug price negotiations”.
Behind the success of the negotiations, it is inseparable from the government, but the negotiations are not based on administrative instructions. We must speak with strength. Our chips are “to change the price”, “to change the price of medical insurance”. In terms of drug prices, multinational pharmaceutical companies rarely compromise, and they are basically incapable, and it is not easy to “cut meat”. Guangdong Province once concentrated on bidding for a 22,000 yuan anti-breast cancer imported drug, which only dropped 0.21 yuan, and the price reduction was only one in 100,000. The imported medicine is so irreplaceable that the emperor’s daughter is not married, and we still lack the bargaining power to bargain.
Winning negotiations is also inseparable from the growth of domestically produced innovative drugs. For example, ectinib hydrochloride for the treatment of lung cancer is considered to be “made in China, Iressa”, which was developed over 8 years and is completely self-originating with a new class of drugs. As the world's third and Asia's first listed lung cancer targeted anticancer drug, it broke the monopoly of imported targeted drugs and made more lung cancer patients at a price lower than 30% — 40% of imported drugs. Use targeted anticancer drugs.
“No innovation, no innovation, no slow innovation”. To form a lot of innovation and speed up the progress of new drug research and development in China, we need institutional and policy support, and we need the source of innovation. Follow-up innovation is dubbed in the industry as the “Me-too” (me too) model. According to public information, among the 1.1 new drug varieties declared in the first half of 2014, the largest proportion of anti-tumor drugs accounted for 1/4, almost all called “something”, Me-too, which is clinically indistinguishable. Products, even if listed, will soon be eliminated.
Insufficient innovation ability at the source is not unrelated to the lack of clinical participation, clinical and research and development. On the one hand, the development of new drugs can not effectively meet the clinical needs, mostly large road goods, can not get a wide range of clinical applications, can not stimulate the development of research; on the other hand, clinical needs always have to fill, imported drugs are still "killer", domestically produced drugs The generic drugs that always follow the footsteps cannot form differentiated competitive strength. Looking at the international market, the US Food and Drug Administration has always been "satisfying clinical needs", and throughout its new drug review concept, it is: drugs that can significantly benefit patients and have clinical advantages compared with existing drugs. In order to be approved for listing, to achieve a positive interaction between clinical and research and development.
Of course, getting through the clinical and research and development barriers is not to let doctors do research and development, but to help accurately calibrate the direction. Let the power of innovation flow in full, so that the drug pricing power of big countries will not fall by, and it will be better to reduce the burden of drugs for ordinary people.